Clarient Receives US and European Patents for Protein Biomarker-Based Mammostrat Breast Cancer Test | GenomeWeb

This story originally ran on Aug. 18.

By Adam Bonislawski

Diagnostics firm Clarient said last week that it has received US and European patents for its Mammostrat breast cancer test, which it plans to release in the US later this year.

The company is completing clinical validation and assay development and training its sales force in preparation for a Q4 launch of the protein biomarker-based diagnostic, Clarient senior vice president of technology Rob Seitz told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.